Fiche publication
Date publication
septembre 1998
Journal
Nucleic acids research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CHAMBON Pierre
,
Dr METZGER Daniel
Tous les auteurs :
Brocard J, Feil R, Chambon P, Metzger D
Lien Pubmed
Résumé
We have developed a new ligand-dependent chimeric recombinase (Cre-GRdex) by fusing the site-specific Cre recombinase to the ligand binding domain (LBD) of a mutant human glucocorticoid receptor (GRdex). The synthetic glucocorticoid receptor (GR) ligands dexamethasone, triamcinolone acetonide and RU38486efficiently induce recombinase activity in F9 murine embryonal carcinoma cells expressing constitutively Cre-GRdex. In contrast, no recombinase activity was detected in the absence of ligand or in the presence of the natural GR ligands corticosterone, cortisol or aldosterone. Moreover, physiological concentrations of these natural GR ligands do not affect Cre-GRdexrecombinase activity induced by dexamethasone. Thus, as previously shown using Cre-oestrogen receptor (ER) fusion proteins, Cre-GRdexmight be useful for achieving loxP site-directed mutagenesis in cultured cells and spatio-temporally controlled somatic cell mutagenesis in transgenic mice.
Mots clés
Aldosterone, pharmacology, Animals, Corticosterone, pharmacology, Dexamethasone, pharmacology, Glucocorticoids, pharmacology, Humans, Hydrocortisone, pharmacology, Integrases, biosynthesis, Ligands, Mice, Mifepristone, pharmacology, Mutation, Receptors, Glucocorticoid, biosynthesis, Recombinant Fusion Proteins, biosynthesis, Recombination, Genetic, Transcriptional Activation, Triamcinolone Acetonide, pharmacology, Viral Proteins
Référence
Nucleic Acids Res.. 1998 Sep;26(17):4086-90
